Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 15Stomach Neoplasms 6Neoplasms 2Inflammatory Breast Neoplasms 2Esophageal Neoplasms 2pCR Rate 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Carcinoma 1Epstein-Barr Virus Infections 1Cardiotoxicity 1Breast Neoplasms, Male 1

Interventions

pembrolizumab 2Sunitinib 2Cisplatin 2Brentuximab Vedotin 2tremelimumab 1pralsetinib 1keyhole-limpet hemocyanin 1durvalumab 1Tetanus Toxoid 1Sirolimus 1Plicamycin 1Pemetrexed 1Paclitaxel 1Genistein 1Gemcitabine 1Gefitinib 1Erlotinib Hydrochloride 1Epirubicin 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms, Germ Cell and Embryonal × Epirubicin × Clear all
NCT00198172 2014-06-03

Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors

Indiana University

Phase 2 Terminated
37 enrolled

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡